SAVA Stock Price: Cassava Sciences Inc. drops after record-setting day from analyst upgrade

NASDAQ:SAVA fell nearly 10% on Tuesday following a near 90% rise to start the week.
Analyst upgrades followed after Cassava’s positive announcement regarding its Alzheimer’s clinical trials.

Stocks Reporter FXStreet

NASDAQ:SAVA pulled back on Tuesday after nearly doubling in price on Monday after Wall Street analysts were bullish on the biotech’s results from a Phase 2B clinical trial of their Alzheimer’s treatment Sumifilam. Shares fell 9.42% to close Tuesday’s trading session at $7.02 which is still well above its 50-day and 200-day moving averages. This comes after the stock skyrocketed by over 145% on Monday following the Cassava’s announcement. Trading volume has been high the last couple of days with over 14 million shares being traded on Tuesday compared to the average trading volume of 4 million.

Sumifilam showed a response rate of patients who showed improvements of 98% which is wonderful news for the company after news in May came out that the trial failed to achieve its primary endpoints. The reversal in the treatment’s performance was music to investors' ears as the micro-cap biotech company based out of Austin, Texas nearly doubled its market cap in the span of 24 hours. Maxim analyst Jason McCarthy upgraded his stance to buy and hold and eagerly announced a new long-term price target of $14. McCarthy used 2025 as the key year in which the finalized drug approval and potential launch would happen so investors do have a bit of a longer-term horizon if McCarthy is accurate in his claims.

SAVA stock forecast

In the short-term, SAVA may have already accomplished a bulk of its growth over the last couple of days. Cassava hopes to have Phase 3 trials for Sumifilam to begin by late 2021 and is set to last a few years so McCarthy’s time estimates may be spot on. Investors should be in it for the long haul now as a successful Phase 3 could run the stock price up again and establish Cassava as a leader in the field of Alzheimer’s treatments.

Author

Stocks Reporter

FXStreet

AUD/USD consolidates above 0.7000; remains close to monthly top

AUD/USD holds steady above 0.7000 during the Asian session on Friday, trading just below the previous day's monthly low amid diverging forces. A hawkish RBA continues to support the Aussie, while the recent decline in US bond yields keeps the US Dollar depressed near a three-week low. However, oil-driven inflation fears reinforce Fed hike bets, which, along with geopolitical risks, could benefit the safe-haven buck and cap the currency pair.

USD/JPY bounces off one-month low; climbs to 157.00 amid reviving USD demand

USD/JPY rebounds from the 156.00 neighborhood, or a one-month low touched during Friday’s Asian session, with bulls looking to extend momentum beyond 157.00 amid the emergence of some US Dollar buying. Meanwhile, Japan's National CPI rose to a nine-month peak and reaffirmed BoJ rate-hike bets, which could support the Japanese Yen and cap gains for the currency pair.

Gold treads water around $4,000

Gold prices maintain its offered stance in place at the end of the week, hovering around the key $4,000 threshold per troy ounce. The persistent selling bias in the precious metal comes amid decent gains in the US Dollar and an acceptable rebound in US Treasury yields across the curve, all alongside further upside traction in crude oil prices.

Crypto Today: Bitcoin holds the 50-day EMA as Ethereum and XRP face structural resistance

Bitcoin gradually ticks up on Friday, trading above $81,000. The Crypto King has recently defended structural support near $80,000, reinforcing the prevailing bullish outlook. Ethereum similarly edges higher above $2,400, while Ripple trades above $1.32 after testing support around $1.30.

The French bond panic is overdone. Here's what the market is misreading

France's 10-year government bond yield has climbed above 5%, reigniting fears of a sovereign debt crisis in the Eurozone. With public debt exceeding €3.5 trillion, persistent budget deficits and a fragmented political landscape, investors are increasingly questioning the French government's ability to stabilize its finances.

What November 3 means for the Fed's rate path and the US Dollar

The USD faces a decisive period ahead of the November 3 midterm elections. While markets anticipate another interest rate increase from the Fed in December, the battle for control of Congress could reshape fiscal policy expectations and, indirectly, the path of US monetary policy in 2027.